Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 5, 2002, Pages 735-742

  Igawa, Masayuki ^a   Aonuma, Kazutaka ^a   Okamoto, Yoshihiro ^a   Hiroe, Michiaki ^b   Hiraoka, Masayasu ^b   Isobe, Mitsuaki ^b  

^a YOKOSUKA KYOSAI HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Class III anti arrhythmic agent; Electrophysiologic study; Nifekalant; Ventricular tachycardia

Indexed keywords

AMIODARONE; DOFETILIDE; NIFEKALANT; PROCAINAMIDE; SOTALOL;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; FEMALE; HEART INFARCTION; HEART PROARRHYTHMIA; HEART VENTRICLE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HYPOTENSION; MALE; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; REFRACTORY PERIOD; SIDE EFFECT;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCAINAMIDE; PYRIMIDINONES; TACHYCARDIA, VENTRICULAR;

EID: 0036872362     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200211000-00011     Document Type: Article

References (19)

1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
2. Cairns JA, Connolly SJ, Roberts R, et al, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349: 675-82.
3. Julian DG, Camm AJ, Frangin G, et al., for the European Myocardial Infarct Amiodarone Trial Investigators: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction. EMIAT. Lancet 1997;349:667-674
4. Mason JW, for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329:445-51.
5. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991;121:158-71.
6. Bashir Y, Thomsen PEB, Kingma JH, et al., for the Dofetilide Arrhythmia Study Group. Electrophysiologic-profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1995; 76:1040-4.
7. Kamiya J, Ishii M, Yoshihara K, et al. MS-551: Pharmacological profile of a novel class III antiarrhythmic agent. Drug Dev Res 1993;30:37-44.
8. Nakaya H, Tohse N, Takeda Y, et al. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993;109:157-63.
9. Kondoh K, Hashimoto H, Nishiyama H, et al. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol 1994;23: 674-80.
10. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 1992; 58:107-15.
11. Mitchell LB, Sheldon RS, Gillis AM, et al. Definition of predicted effective antiarrhythmic drug therapy for ventricular tachyarrhythmias by the electrophysiologic study approach: Randomized comparison of patient response criteria. J Am Coll Cardiol 1997;30:1346-53.
12. Iesaka Y, Nogami A, Aonuma K, et al. Prognostic significance of sustained monomorphic ventricular tachycardia induced by programmed ventricular stimulation using up to triple extrastimuli in survivors of acute myocardial infarction. Am J Cardiol 1990;65:1057-63.
13. Nogami A, Aonuma K, Takahashi A, et al. Usefulness of early versus late programmed ventricular stimulation in acute myocardial infarction. Am J Cardiol 1991;68:13-20.
14. Waxman HL, Buxton AE, Sadowski LM, et al. The response to procainamide during electrophysiologic study for ventricular tachyarrhythmias predicts the response to other medications. Circulation 1983;67:30-7.
15. Furukawa T, Rozanski JJ, Moroe K, et al. Efficacy of procainamide on ventricular tachycardia: Relation to prolongation of refractoriness and slowing of conduction. Am Heart J 1989;118:702-8.
16. Zipes DP. Management of cardiac arrhythmias: Pharmacological, electrical, and surgical techniques. In: Braunwald E, ed. Heart disease. Philadelphia: WB Saunders, 1997:602-4.
17. Young GD, Kerr CR, Mohama R, et al. Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. Am J Cardiol 1994;73:677-82.
18. Zhu J, Haines DE, Lerman BB, et al. Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. Circulation 1987;76:802-9.
19. Kowey PR, Marinchak RA, Rials SJ, et al. Intravenous amiodarone. J Am Coll Cardiol 1997;29:1190-8.